Developer docs
API playgroundTry for free, no card

Search company profiles

Kazmira

Full company profile

uuid000dk7c

Namestring
Kazmira
Legal namestring
Kazmira LLC
Websiteurl
kazmira-llc.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Kazmira is a vertically integrated prescription cannabinoid company that pairs a LegitScript-certified 503A compounding pharmacy (Kazmira Pharmacy) with a direct-to-consumer telehealth platform (Cope Now) to deliver THC-free, prescription-only CBD at clinically effective doses. Founded in 2017 and headquartered in Watkins, Colorado, the company is led by co-founder and CEO Pulak Sharma. Kazmira Pharmacy, launched in January 2026, is described as the first licensed 503A compounding pharmacy in the United States offering pure, THC-free, prescription-only CBD. Cope Now, launched in May 2026 in Colorado, connects patients with licensed clinicians for virtual consultations and prescription fulfillment through the in-house pharmacy, addressing a dosing gap between typical consumer CBD use (under 50 mg/day) and clinically effective therapeutic doses (200-400 mg/day).

The underlying technology centers on pharmaceutical-grade compounding and a vertically integrated telehealth-to-pharmacy workflow rather than a proprietary software or AI stack. The business model generates revenue through telehealth consultation services (described as recurring) and per-prescription sales of pharmacy-compounded CBD. Initial go-to-market is direct-to-consumer via the Cope Now telehealth platform, with an enterprise sales posture toward healthcare provider networks as the company scales into additional states.

The strategic posture is regulatory-tail-driven: Kazmira is positioned as the compliant prescription alternative as federal legislation (H.R. 5371, passed November 2025 with enforcement beginning November 2026) and the December 2025 Executive Order rescheduling cannabis to Schedule III restrict the over-the-counter hemp-derived CBD market. The company has publicly committed to expanding into 20 or more additional states, with Arizona, Florida, Texas, and Utah named as 2026 targets, against a global hemp oil market projected to reach $27.2 billion by 2030.

Short descriptiontext

Kazmira operates a vertically integrated prescription CBD platform combining the nation's first 503A compounding pharmacy with a direct-to-consumer telehealth service, delivering clinically dosed THC-free CBD to patients who require treatment beyond over-the-counter wellness products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWatkins, United States
HQ citystring
Watkins
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
compounding pharmacy services, prescription CBD formulations, telehealth cannabis consultations, hemp-derived cannabinoid ingredients, pharmacy-compounded therapeutics
Industry3 codes
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYHSABALAL
Compounding & Customized Medication Management Support
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code3 codes
  • Pharmacies and Drug Retailers45611
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Retail-Drug Stores And Proprietary Stores5912
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Compounding Pharmacy and Telehealth Prescription CBD
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Telehealth Prescription Services
TypeSubscription Recurring
Description

Revenue generated from virtual consultations with licensed clinicians for prescription cannabis and CBD evaluation and treatment plans through the Cope Now platform.

prnewswire.com
2Prescription Compounded CBD Products
TypeOthers
Description

Sales of pharmacy-compounded, prescription-only CBD products through the vertically integrated Kazmira Pharmacy, serving patients who require clinically effective doses not available through over-the-counter products.

briefglance.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Kazmira operates a vertically integrated prescription cannabinoid platform combining Kazmira Pharmacy, the first licensed 503A compounding pharmacy in the United States offering THC-free, prescription-only CBD, with the Cope Now telehealth platform that delivers virtual consultations with licensed clinicians for personalized CBD treatment plans. The pharmacy compounds pure, THC-free CBD formulations at clinically effective doses of 200-400 mg/day, addressing the dosing gap between typical over-the-counter consumer CBD use (under 50 mg/day) and therapeutic thresholds, with multi-state expansion planned.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Addresses dosing requirements of 200-400 mg/day versus typical consumer use of under 50 mg/day
Product overview1 text field

Kazmira Therapeutics operates a vertically integrated prescription cannabis and CBD product portfolio combining telehealth services with a licensed compounding pharmacy. The core offerings include Kazmira Pharmacy (the nation's first 503A compounding pharmacy offering THC-free, prescription-only CBD) and Cope Now (a telehealth platform for virtual consultations with licensed clinicians to prescribe personalized CBD treatments). These products work together through a vertically integrated model where telehealth evaluations connect patients directly to pharmacy-compounded CBD products, addressing the dosing gap between typical consumer CBD use and clinically effective therapeutic doses.

Product and service3 records
1Cope Now
CategoryTelehealth
Description

A telehealth platform providing patients with prescription-only, pharmacy-compounded CBD through virtual consultations with licensed clinicians, delivering clinically effective CBD doses (200-400 mg/day) compared to typical consumer use (under 50 mg/day), launching in Colorado with planned multi-state expansion.

2Kazmira Pharmacy (503A Compounding)
CategoryCompounding Pharmacy
Description

First licensed 503A compounding pharmacy in the United States specializing in pure THC-free, prescription-only CBD; LegitScript-certified pharmacy providing evidence-based, clinically prescribed cannabis medicine through a vertically integrated model with the Cope Now telehealth platform.

3Hemp-derived cannabinoid ingredients
CategoryActive Pharmaceutical Ingredients
Description

Science-based manufactured hemp-derived cannabinoid ingredients that serve as the underlying raw inputs for Kazmira Pharmacy's compounded prescription CBD formulations.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Tilray Brands
TypeBroad incumbent
Description

Tilray is a large, publicly traded global cannabis company with operations across cultivation, processing, distribution, and branded medical cannabis products. It is a broad incumbent comparable to Kazmira in the prescription/medical cannabis category but operates across a much wider portfolio and geography.

2PrestoDoctor
TypeDirect peer
Description

PrestoDoctor provides online medical cannabis evaluations and recommendations via telehealth across multiple U.S. states. It is a direct peer to Kazmira's Cope Now in the cannabis-specific telehealth recommendation space, with comparable multi-state reach ambitions.

TypeDirect peer
Description

Veriheal is a cannabis telehealth and patient access platform offering virtual consultations with physicians for medical marijuana cards and treatment plans. Like Kazmira's Cope Now, it operates a direct-to-consumer prescription cannabis funnel, making it a direct peer in telehealth-driven cannabis access.

TypeBroad incumbent
Description

Curaleaf is a large U.S. multi-state cannabis operator with dispensaries, cultivation, and a growing medical/pharmacy footprint. It is a broad incumbent comparable to Kazmira's medical cannabis dispensary + pharmacy patient services model, though at substantially larger scale and broader product scope.

TypeDirect peer
Description

NuggMD is one of the largest cannabis telehealth platforms in the U.S., connecting patients with licensed physicians for medical cannabis recommendations and prescriptions. It is directly comparable to Kazmira's Cope Now platform on the telehealth + prescription cannabis model, though NuggMD is not vertically integrated with a compounding pharmacy.

TypeDirect peer
Description

Dutchie is a leading cannabis e-commerce and retail technology platform that has expanded into telehealth and payments infrastructure for dispensaries. It overlaps with Kazmira's telehealth + pharmacy fulfillment model and serves a similar cannabis patient audience.

TypeBroad incumbent
Description

Charlotte's Web is a leading hemp-derived CBD wellness brand selling tinctures, capsules, and topicals through retail and DTC channels. It is a broad incumbent in hemp-derived CBD that Kazmira's prescription model is positioned against as regulations tighten OTC offerings.

TypeBroad incumbent
Description

Hims & Hers is a scaled direct-to-consumer telehealth and prescription platform with national reach across multiple therapeutic categories. It is a broad incumbent comparable to Kazmira's telehealth-plus-prescription model, with substantially greater brand awareness and customer acquisition infrastructure.

TypeDirect peer
Description

Empower Pharmacy is a large 503A and 503B compounding pharmacy producing customized medications, including hormone and wellness preparations. It is directly comparable to Kazmira Pharmacy on the compounding pharmacy infrastructure side, though it does not currently focus on cannabis-specific formulations.

TypeDirect peer
Description

Green Health Docs is a multi-state cannabis telehealth and certification provider offering online medical marijuana evaluations. It directly mirrors Kazmira's Cope Now in the cannabis telehealth recommendation category and shares the multi-state expansion thesis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kazmira

Compounding Pharmacy and Telehealth Prescription CBDkazmira-llc.com

Kazmira operates a vertically integrated prescription CBD platform combining the nation's first 503A compounding pharmacy with a direct-to-consumer telehealth service, delivering clinically dosed THC-free CBD to patients who require treatment beyond over-the-counter wellness products.

What Kazmira does

Kazmira is a vertically integrated prescription cannabinoid company that pairs a LegitScript-certified 503A compounding pharmacy (Kazmira Pharmacy) with a direct-to-consumer telehealth platform (Cope Now) to deliver THC-free, prescription-only CBD at clinically effective doses. Founded in 2017 and headquartered in Watkins, Colorado, the company is led by co-founder and CEO Pulak Sharma. Kazmira Pharmacy, launched in January 2026, is described as the first licensed 503A compounding pharmacy in the United States offering pure, THC-free, prescription-only CBD. Cope Now, launched in May 2026 in Colorado, connects patients with licensed clinicians for virtual consultations and prescription fulfillment through the in-house pharmacy, addressing a dosing gap between typical consumer CBD use (under 50 mg/day) and clinically effective therapeutic doses (200-400 mg/day).

The underlying technology centers on pharmaceutical-grade compounding and a vertically integrated telehealth-to-pharmacy workflow rather than a proprietary software or AI stack. The business model generates revenue through telehealth consultation services (described as recurring) and per-prescription sales of pharmacy-compounded CBD. Initial go-to-market is direct-to-consumer via the Cope Now telehealth platform, with an enterprise sales posture toward healthcare provider networks as the company scales into additional states.

The strategic posture is regulatory-tail-driven: Kazmira is positioned as the compliant prescription alternative as federal legislation (H.R. 5371, passed November 2025 with enforcement beginning November 2026) and the December 2025 Executive Order rescheduling cannabis to Schedule III restrict the over-the-counter hemp-derived CBD market. The company has publicly committed to expanding into 20 or more additional states, with Arizona, Florida, Texas, and Utah named as 2026 targets, against a global hemp oil market projected to reach $27.2 billion by 2030.

Kazmira firmographics

Firmographics
Name
Kazmira
Legal name
Kazmira LLC
Website
https://kazmira-llc.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Kazmira operates a vertically integrated prescription CBD platform combining the nation's first 503A compounding pharmacy with a direct-to-consumer telehealth service, delivering clinically dosed THC-free CBD to patients who require treatment beyond over-the-counter wellness products.
Ownership category
akta.pro rank

Kazmira industry classification

Industry
Product category
Compounding Pharmacy and Telehealth Prescription CBD
NAICS
Pharmacies and Drug Retailers (45611), Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC
Retail-Drug Stores And Proprietary Stores (5912), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYHSABALAL
Compounding & Customized Medication Management Support
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support
SECONDARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Compounding pharmacy services
  • Prescription CBD formulations
  • Telehealth cannabis consultations
  • Hemp-derived cannabinoid ingredients
  • Pharmacy-compounded therapeutics

Where Kazmira is headquartered

Location

Headquarters

HQ city
Watkins
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Kazmira business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Telehealth Prescription Services: Revenue generated from virtual consultations with licensed clinicians for prescription cannabis and CBD evaluation and treatment plans through the Cope Now platform.
  2. Prescription Compounded CBD Products: Sales of pharmacy-compounded, prescription-only CBD products through the vertically integrated Kazmira Pharmacy, serving patients who require clinically effective doses not available through over-the-counter products.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels1 record

Kazmira product offering

Product offering

Core offering

Kazmira operates a vertically integrated prescription cannabinoid platform combining Kazmira Pharmacy, the first licensed 503A compounding pharmacy in the United States offering THC-free, prescription-only CBD, with the Cope Now telehealth platform that delivers virtual consultations with licensed clinicians for personalized CBD treatment plans. The pharmacy compounds pure, THC-free CBD formulations at clinically effective doses of 200-400 mg/day, addressing the dosing gap between typical over-the-counter consumer CBD use (under 50 mg/day) and therapeutic thresholds, with multi-state expansion planned.

Product overview

Kazmira Therapeutics operates a vertically integrated prescription cannabis and CBD product portfolio combining telehealth services with a licensed compounding pharmacy. The core offerings include Kazmira Pharmacy (the nation's first 503A compounding pharmacy offering THC-free, prescription-only CBD) and Cope Now (a telehealth platform for virtual consultations with licensed clinicians to prescribe personalized CBD treatments). These products work together through a vertically integrated model where telehealth evaluations connect patients directly to pharmacy-compounded CBD products, addressing the dosing gap between typical consumer CBD use and clinically effective therapeutic doses.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cope Now A telehealth platform providing patients with prescription-only, pharmacy-compounded CBD through virtual consultations with licensed clinicians, delivering clinically effective CBD doses (200-400 mg/day) compared to typical consumer use (under 50 mg/day), launching in Colorado with planned multi-state expansion.
  • Kazmira Pharmacy (503A Compounding) First licensed 503A compounding pharmacy in the United States specializing in pure THC-free, prescription-only CBD; LegitScript-certified pharmacy providing evidence-based, clinically prescribed cannabis medicine through a vertically integrated model with the Cope Now telehealth platform.
  • Hemp-derived cannabinoid ingredients Science-based manufactured hemp-derived cannabinoid ingredients that serve as the underlying raw inputs for Kazmira Pharmacy's compounded prescription CBD formulations.

Quantifiable outcome

  • Addresses dosing requirements of 200-400 mg/day versus typical consumer use of under 50 mg/day

Companies that use Kazmira

Customer profile

Segments2 records

Ideal customer profiles2 records

Kazmira technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Kazmira partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Kazmira competitors and assessment

Company assessment

Broad incumbents

  • Tilray Brands: Tilray is a large, publicly traded global cannabis company with operations across cultivation, processing, distribution, and branded medical cannabis products. It is a broad incumbent comparable to Kazmira in the prescription/medical cannabis category but operates across a much wider portfolio and geography.
  • Curaleaf Holdings: Curaleaf is a large U.S. multi-state cannabis operator with dispensaries, cultivation, and a growing medical/pharmacy footprint. It is a broad incumbent comparable to Kazmira's medical cannabis dispensary + pharmacy patient services model, though at substantially larger scale and broader product scope.
  • Charlotte's Web Holdings: Charlotte's Web is a leading hemp-derived CBD wellness brand selling tinctures, capsules, and topicals through retail and DTC channels. It is a broad incumbent in hemp-derived CBD that Kazmira's prescription model is positioned against as regulations tighten OTC offerings.
  • Hims & Hers Health: Hims & Hers is a scaled direct-to-consumer telehealth and prescription platform with national reach across multiple therapeutic categories. It is a broad incumbent comparable to Kazmira's telehealth-plus-prescription model, with substantially greater brand awareness and customer acquisition infrastructure.

Direct peers

  • PrestoDoctor: PrestoDoctor provides online medical cannabis evaluations and recommendations via telehealth across multiple U.S. states. It is a direct peer to Kazmira's Cope Now in the cannabis-specific telehealth recommendation space, with comparable multi-state reach ambitions.
  • Veriheal: Veriheal is a cannabis telehealth and patient access platform offering virtual consultations with physicians for medical marijuana cards and treatment plans. Like Kazmira's Cope Now, it operates a direct-to-consumer prescription cannabis funnel, making it a direct peer in telehealth-driven cannabis access.
  • NuggMD: NuggMD is one of the largest cannabis telehealth platforms in the U.S., connecting patients with licensed physicians for medical cannabis recommendations and prescriptions. It is directly comparable to Kazmira's Cope Now platform on the telehealth + prescription cannabis model, though NuggMD is not vertically integrated with a compounding pharmacy.
  • Dutchie: Dutchie is a leading cannabis e-commerce and retail technology platform that has expanded into telehealth and payments infrastructure for dispensaries. It overlaps with Kazmira's telehealth + pharmacy fulfillment model and serves a similar cannabis patient audience.
  • Empower Pharmacy: Empower Pharmacy is a large 503A and 503B compounding pharmacy producing customized medications, including hormone and wellness preparations. It is directly comparable to Kazmira Pharmacy on the compounding pharmacy infrastructure side, though it does not currently focus on cannabis-specific formulations.
  • Green Health Docs: Green Health Docs is a multi-state cannabis telehealth and certification provider offering online medical marijuana evaluations. It directly mirrors Kazmira's Cope Now in the cannabis telehealth recommendation category and shares the multi-state expansion thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Kazmira social profiles

Digital presence

Kazmira compliance and trust

Trust signal

Compliance2 records

Kazmira financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kazmira leadership team

Management profile

Number of profiles

Profiles1 record

Kazmira subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Kazmira funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kazmira M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kazmira

What does Kazmira do?

Kazmira operates a vertically integrated prescription cannabinoid platform combining Kazmira Pharmacy, the first licensed 503A compounding pharmacy in the United States offering THC-free, prescription-only CBD, with the Cope Now telehealth platform that delivers virtual consultations with licensed clinicians for personalized CBD treatment plans. The pharmacy compounds pure, THC-free CBD formulations at clinically effective doses of 200-400 mg/day, addressing the dosing gap between typical over-the-counter consumer CBD use (under 50 mg/day) and therapeutic thresholds, with multi-state expansion planned.

Is Kazmira a public or private company?

Kazmira is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Kazmira founded?

Kazmira was founded in 2017. It employs 11 to 50 people.

Where is Kazmira based?

Kazmira is headquartered in Watkins, United States, in the North America region.

How does Kazmira make money?

Two revenue lines are on record. Telehealth Prescription Services are the primary driver. The others are prescription Compounded CBD Products.

Who are Kazmira's main competitors?

Broad incumbents on record are Tilray Brands, Curaleaf Holdings, Charlotte's Web Holdings and Hims & Hers Health. Direct peers are PrestoDoctor, Veriheal, NuggMD, Dutchie, Empower Pharmacy and Green Health Docs.

Does Kazmira have an API?

No public API is recorded for Kazmira.

What industry is Kazmira in?

Kazmira's product category is Compounding Pharmacy and Telehealth Prescription CBD. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of HSABALAL, Compounding & Customized Medication Management Support. Its NAICS code is 45611 and its SIC code is 5912.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BriefglancePrescription CBD via Telehealth: A New Era Dawns as Rules TightenKazmira Therapeutics has launched Cope Now, a telehealth platform in Colorado (launching May 28, 2026) providing patients with prescription-only, pharmacy-compounded CBD through virtual consultations with licensed clinicians. The platform is a direct response to federal legislation H.R. 5371 passed in November 2025, which closes the 2018 Farm Bill's "hemp loophole" and will render up to 95% of current hemp-derived intoxicating products federally illegal when enforcement begins in November 2026. The service aims to address the dosing gap between typical consumer use (under 50 mg/day) and clinically effective doses (200-400 mg/day), operating through a vertically integrated model combining telehealth with Kazmira Pharmacy, the nation's first 503A compounding pharmacy.PR NewswirePrescription cannabis telehealth platform launches in Colorado, with multi-state expansion plannedKazmira Therapeutics launched Cope Now, a telehealth platform in Colorado for prescription cannabis and CBD, with plans to expand to other states. The platform offers clinician-led evaluation and personalized CBD treatment, addressing regulatory changes in hemp-derived products.PR NewswireFirst-of-its-kind medical grade cannabis pharmacy launches in ColoradoKazmira Therapeutics announced the launch of Kazmira Pharmacy, described as the first licensed 503A compounding pharmacy in the United States offering THC-free, prescription-only CBD, operating from Colorado. The launch strategically positions the company to capitalize on the December 2025 Executive Order rescheduling cannabis to Schedule III, which restricts over-the-counter CBD products containing more than 0.4 mg of THC. While initially launching in Colorado, Kazmira Pharmacy is structured to expand into 20 or more additional states including Arizona, Florida, Texas, and Utah by 2026.CannabisbusinesstimesFirst-of-its-Kind Medical-Grade Cannabis Pharmacy Launches in ColoradoKazmira Therapeutics announced the launch of Kazmira Pharmacy, a first-of-its-kind prescription-only 503A compounding pharmacy specializing in pure CBD without THC, in Colorado. The pharmacy is LegitScript-certified and positioned to move CBD from over-the-counter wellness products to evidence-based, clinically prescribed medicine. The company plans to expand to 20 or more additional states, including Arizona, Florida, Texas and Utah, in 2026.PR NewswireGlobal CBD (Cannabidiol) Oil Market Report 2020-2027: Medical Community Recognition of Potential Value and Legalization Driving DemandResearchAndMarkets.com announced the addition of a global Cannabidiol (CBD) Oil market report covering 2020-2027, projecting the market size to reach USD 24.08 billion by 2027. The report attributes growth to increasing medical community recognition of CBD's therapeutic value and expanding legalization across regions, with WHO and U.S. National Academies affirming cannabis-based treatments. In June 2020, Perrigo Company plc entered the market through a strategic investment, acquiring a 20% equity stake in Kazmira LLC, a Colorado-based CBD products supplier.DBusiness MagazineWest Michigan’s Perrigo Enters CBD Market With $50M Stake in KazmiraPerrigo Co. announced a $50 million investment and 20% equity stake in Kazmira, a THC-free CBD supplier, with $15 million paid at close and the balance within 18 months. The deal includes a long-term supply agreement and a two-phase partnership to scale production and launch CBD products globally.Business InsiderThe CEO of one of the world's largest generic drugmakers tells us why he's making a $50 million bet on CBDPerrigo is investing $50 million for a 20% stake in Colorado CBD maker Kazmira, paying $15 million upfront and the rest over 18 months. CEO Murray Kessler said the move positions Perrigo as a self-care company, aiming to clean up the supply chain and launch store-brand CBD products.PR NewswirePerrigo Partners With Kazmira LLC To Enter CBD Market Through A Two-Phased, Science-Based ApproachPerrigo Company plc announced a strategic partnership with Kazmira LLC, acquiring an approximately 20% equity stake for $50 million, to enter the rapidly growing CBD market through a two-phased approach. Under the agreement, the companies will collaborate to scale up Kazmira's Colorado-based facilities to cGMP standards to produce THC-free CBD products, with Kazmira serving as the exclusive supplier for the U.S. store brand market. In the second phase, Perrigo plans to leverage the partnership to launch THC-free hemp-based CBD products across multiple global markets, targeting what it describes as an emerging industry lacking rigorous quality standards and regulatory expertise.